Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 adjunctive therapy for partial onset seizures
ACTRN12616000510448Phase 2Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Jul 2016
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Zygel in epilepsy and Focal Onset Epilepsy (3 arms), sponsored by Zynerba Pharmaceuticals. Primary endpoint: Composite Primary Outcome 1. Started Jul 2016; status: completed.
02
Drugs
Zygel
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on ACTRN12616000510448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000510448.